Takeda Pharmaceutical (TAK) Other Accumulated Expenses (2017 - 2026)

Takeda Pharmaceutical's Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $3.8 billion for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 3.72% year-over-year to $3.8 billion; the TTM figure through Mar 2026 stood at $3.8 billion (down 3.72% YoY), while the FY2026 annual figure was $3.9 billion, changed 0.15% from the prior year.
• Other Accumulated Expenses was $3.8 billion for Q1 2026 at Takeda Pharmaceutical, up from $3.7 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $5.0 billion in Q1 2022 to a low of $3.3 billion in Q3 2024.
• Historically, Other Accumulated Expenses has averaged $4.0 billion across 5 years, with a median of $4.0 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses fell 16.13% in 2024, then grew 2.51% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $4.5 billion in 2022, then dropped by 12.6% to $4.0 billion in 2023, then fell by 5.98% to $3.7 billion in 2024, then retreated by 0.87% to $3.7 billion in 2025, then increased by 1.99% to $3.8 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $3.8 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.4 billion (Q3 2025), per Business Quant data.